Drugs /

tvb-2640

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, TVB-2640 binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.

Clinical Trials

View Clinical Trials for tvb-2640

Tvb-2640 has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating tvb-2640, 1 is phase 1 (1 open) and 3 are phase 2 (3 open).

ER Expression, ER Positive, and ERBB2 Amplification are the most frequent biomarker inclusion criteria for tvb-2640 clinical trials.

Astrocytoma, breast carcinoma, and colon carcinoma are the most common diseases being investigated in tvb-2640 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tvb-2640
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tvb-2640 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
fasn inhibitor tvb-2640, fasn inhibitor tvb-2640
Drug Target(s) [2]:
FASN
NCIT ID [1]:
C118285

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.